Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

CounterACT: U.S. Funding Early Stage Drug Discovery of Countermeasures Against Chemical Threats

by Global Biodefense Staff
March 21, 2022
State Department: Reducing Revisionist State Biological and Chemical Weapons Threats

The National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program has announced intentions to open a funding solicitation to support early-stage development of new and repurposed drug candidates to mitigate the health effects resulting from exposure to chemical threats.

Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals (TICs), pesticides, and pharmaceutical-based agents. The overall scope of this research initiative will include discovery and validation of therapeutic targets through preclinical characterization (i.e., specificity, affinity, potency, target selectivity, post-exposure efficacy) of lead compounds.

Chemical threats of interest for medical countermeasure development under this effort are those included on the current Department of Homeland Security (DHS) List of Chemicals of Concern (CoC), which is for U.S. Government official use only and cannot be published. However, the following Chemical Toxidromes, grouped by mechanism of action and the toxic effects of the agents, serve as an example of over 200 applicable chemical threat agents.

  • Anticoagulants (brodifacoum, bromadiolone)
  • Blood agents (hydrogen cyanide, hydrogen sulfide)
  • Cholinergic warfare (sarin, soman, VX)
  • Cholinergic pesticides (parathion, chlorpyrifos, phorate, aldicarb)
  • Convulsant (picrotoxin, TETS, strychnine)
  • Hemolytic/Metabolic (arsenic trioxide, thallium sulfate, arsine)
  • Opioids (fentanyl, diacetyl morphine)
  • Lower pulmonary (chlorine, phosgene)
  • Upper pulmonary (ammonia, sulfur dioxide, hydrogen fluoride)
  • Vesicants (sulfur and nitrogen mustard, phosgene oxime)

Applicants are strongly urged to contact the NIH staff to determine if their proposed threat agent targets are of interest for this effort if in doubt.

As this effort is focused on medical countermeasures that can be administered following a mass casualty event, proposals for drugs that must be administered prophylactically (pre-exposure) will not be considered).

Notice of Intent to Publish a Funding Opportunity Announcement for Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early Stage Development (UG3/UH3 Clinical Trial Not Allowed). A trans-NIH effort issued by: National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS). Estimated publication date: 3 May 2022. Estimated application due date: 13 September 2022.

Tags: Chemical WeaponsEditor PickRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC